2.1
Trifluridine–tipiracil (Lonsurf, Servier Laboratories) plus bevacizumab is indicated for 'the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents'.